氟维司群治疗绝经后激素受体阳性晚期乳腺癌的研究进展  

Advances of fulvestrant in treatment of advanced breast cancer in hormone receptor-positive postmenopausal women

作　　者：王佳玉[1] 徐兵河[1] 

机构地区：[1]中国医学科学院肿瘤医院肿瘤内科,北京100021

出　　处：《中国癌症杂志》2016年第5期471-475,共5页China Oncology

摘　　要：以阻断雌激素作用通路为目的的内分泌治疗是晚期乳腺癌的一线治疗选择之一。氟维司群作为雌激素拮抗剂,可通过阻断并降解雌激素受体起作用。目前,临床上使用氟维司群每月250 mg作为一线内分泌治疗后疾病进展或复发的绝经后激素受体阳性晚期乳腺癌的二线治疗方案。相比之下,氟维司群每月500 mg可获得更好的疗效,且不增加新的安全性问题。目前对于氟维司群的研究更多地集中在一线治疗以及与其他药物联用来治疗晚期乳腺癌。该文对氟维司群在激素受体阳性晚期乳腺癌中的研究进展进行了综述。Endocrine therapy targeting estrogen pathway is one of the first-line treatment choices of advanced breast cancer. Fulvestrant is a pure estrogen antagonist that blocks and downgrades estrogen receptor, which makes it effective in the treatment of progression after prior endocrine therapy. Fulvestrant 250 mg per month regime was approved for postmenopausal women with hormone-positive advanced breast cancer after progression or recurrence on antiestrogen therapy. Fulvestrant 500 mg per month regime was approved by the EMA and the US FDA in the same population based on the CONFIRM trial which proved improved efficacy and similar tolerance compared with 250 mg regime. Recent trials were focused in the first-line treatment and combination use with other therapeutics. This review discusses the advances of fulvestrant in postrnenopausal women with hormone-positive advanced breast cancer.

关 键 词：氟维司群 绝经后妇女 激素受体阳性 晚期乳腺癌 

分 类 号：R737.9[医药卫生—肿瘤]